• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cellectis Provides Financial Results for the Second Quarter 2024

    8/6/24 4:30:00 PM ET
    $AZN
    $CLLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email
    • ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL

    • ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment

    • Cash position of $273 million as of June 30, 20241; cash runway projection into 2026

    NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024.

    "Over the past months, we have achieved a significant milestone with the granting of ODD designations by the Food and Drug Administration and the European Commission, complemented by the FDA'S Rare Pediatric Disease Designation. We have overcome major challenges, which reflects our ongoing commitment to innovation. Driven by an unwavering belief in our ability to revolutionize the healthcare field, we continue our pursuit of advancement with the confidence that our work will lead to the launch of a life-saving drug product. Our determination is the engine of our future success" said André Choulika, Ph.D., Chief Executive Officer at Cellectis.

    ________________________

    1 Cash position includes cash, cash equivalents, restricted cash and fixed-term deposits classified as current financial assets. Restricted cash was $5 million as of June 30, 2024. Fixed-term deposits classified as current financial assets were $119 million as of June 30, 2024.

    Pipeline Highlights

    UCART Clinical Programs

    • On June 4, 2024, Cellectis received Orphan Drug Designation (ODD) from the European Commission (EC) for UCART22, for the treatment of acute lymphoblastic leukemia (ALL). The Orphan Drug Designation in the European Union is granted by the EC based on a positive opinion issued by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products. This designation may allow certain regulatory, financial, and commercial incentives to develop medicines for rare diseases where there are no satisfactory treatment options.
    • On July 25, 2024, the FDA designated UCART22 as a drug for a Rare Pediatric Disease (RPDD). This designation may allow to obtain a "Priority Review Voucher" at the time of Biologics License Application (BLA). The FDA also granted ODD to UCART22 product candidate for ALL treatment. Receiving ODD by the FDA may help to expedite and reduce the cost of development, approval, and commercialization of a therapeutic agent.
    • Patients with relapsed/refractory ALL have limited, if any, treatment options, especially for those who have failed prior CD19 directed CAR T-cell therapy and allogeneic stem cell transplant. These designations for UCART22 mark an important step towards developing allogeneic CAR T products that would be readily available for all patients.

    • On August 1, 2024, the FDA granted ODD to Cellectis' CLLS52 (alemtuzumab), an Investigational Medicinal Product (IMP) used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial. The importance of adding alemtuzumab to the lymphodepletion regimen has been demonstrated in Cellectis' BALLI-01 study, where the addition of this lymphodepletion agent to the fludarabine and cyclophosphamide regimen was associated with sustained lymphodepletion and significantly higher UCART22 cell expansion allowing for greater clinical activity.

    • Cellectis continues to focus on the enrollment of patients in the BALLI-01 study, evaluating UCART22 in relapsed or refractory B-cell acute lymphoblastic leukemia, in the NatHaLi-01 study, evaluating UCART20x22 in relapsed or refractory B-cell non-Hodgkin lymphoma, and in the AMELI-01 study, evaluating UCART123 in relapsed or refractory acute myeloid leukemia. We expect to provide updates in the advancements of BALLI-01 until the end of the year 2024.

    Research Data & Preclinical Programs

    Non-viral Gene Therapy Approach for Sickle Cell Disease

    • On June 12, 2024, Cellectis announces the publication of a scientific article in Nature Communications.

    • Cellectis leverages TALEN® technology and a non-viral gene repair template delivery to develop a clinically relevant gene editing process in hematopoietic stem and progenitor cells (HSPCs). This process enables efficient HBB gene correction with high precision, specificity and minimal genomic adverse events. 

    • Applying this HBB gene correction process to SCD patient-HSPCs results in over 50% expression of normal adult hemoglobin in mature red blood cells and in the correction of sickle phenotype, without inducing β-thalassemic phenotype. Edited HSPCs engraft efficiently in an immunodeficient murine model and maintain clinically relevant levels of HBB gene correction events. This comprehensive preclinical data package sets the stage for the therapeutic application of autologous gene corrected HSPCs to address SCD.

    Partnerships

    Licensed Allogeneic CAR T-cell Development Programs

    Anti-CD19 Programs

    Allogene's investigational oncology products utilize Cellectis technologies.

    We have initiated an arbitration proceeding through the Centre de Médiation et d'Arbitrage de Paris. We are requesting that the arbitral tribunal issue a decision (i) terminating the Servier License Agreement, and (ii) requiring Servier to pay us fair financial compensation for losses incurred due to the lack of development of the licensed products and for non-payment of milestone payments for milestones that have been achieved under the Servier License Agreement.

    In May 2024, Allogene announced the execution of an Amendment and Settlement Agreement (the "Servier Amendment"), which amended the license agreement between Servier and Allogene, under which Servier exclusively sublicensed to Allogene its rights under the License Agreement between Cellectis and Servier (the "Servier License"), for the development and commercialization of allogeneic anti-CD19 CAR T cell product candidates in the U.S. (the "Allogene Sublicense"). Allogene disclosed that, pursuant to the Servier Amendment to the Allogene Sublicense, the licensed territory was expanded to include the European Union and the United Kingdom, and Allogene was granted an option to further extend its licensed territory to include China and Japan subject to certain conditions.

    Corporate Updates

    Collaboration and Investment Agreements with AstraZeneca

    • On May 6, 2024, Cellectis announced the completion of the subsequent investment of $140M in Cellectis by AstraZeneca (NASDAQ:AZN) (the "Additional Investment").

    • AstraZeneca subscribed for 10,000,000 "class A" convertible preferred shares and 18,000,000 "class B" convertible preferred shares, in each case at a price of $5.00 per convertible preferred share, issued by the Board of Directors of Cellectis.

    • On the completion date of the Additional Investment, AstraZeneca owned approximately 44% of the share capital and 30% of the voting rights of the Company (based on the number of voting rights outstanding at the time).

    • Following the Additional Investment, Mr. Marc Dunoyer and Dr. Tyrell Rivers have been nominated members of the board of directors of Cellectis, designated by AstraZeneca.

    Annual Shareholders Meeting

    • On June 28, 2024, Cellectis held a shareholders' general meeting at the Biopark auditorium in Paris, France.

    • At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, consistent with the recommendations of the management. The detailed results of the vote and the resolutions are available on Cellectis' website: https://www.cellectis.com/en/investors/general-meetings/

    Financial Results

    The interim condensed consolidated financial statements of Cellectis have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board ("IFRS").

    As from June 1, 2023, and the deconsolidation of Calyxt, which corresponded to the Plants operating segment, we view our operations and manage our business in a single operating and reportable segment corresponding to the Therapeutics segment. For this reason, we are no longer presenting financial measures broken down between our two reportable segments – Therapeutics and Plants. In the appendices of this Q2 2024 financial results press release, Calyxt's results are isolated under "Income (loss) from discontinued operations" for the 6-month period ended June 30, 2023, and are no longer included for the 6-month period ended June 30, 2024, due to the deconsolidation.

    Cash: As of June 30, 2024, Cellectis had $273 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current-financial assets. This compares to $156 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current-financial assets as of December 31, 2023. This $117 million increase is mainly due to cash payments from Cellectis to suppliers of $26 million, including $18 million to R&D suppliers and $8 million to SG&A suppliers, Cellectis' wages, bonuses and social expenses paid of $24 million, the payments of lease debts of $5 million and the repayment of the "PGE" loan of $3 million, partially offset by the $16 million cash received from EIB pursuant to the disbursement of the €15 million Tranche B, $5 million of cash-in from our financial investments, $14 million of cash-in from our revenue, $140 million cash received from AstraZeneca as part of its equity investment in Cellectis.

    With cash and cash equivalents of $149 million and $119 million term deposit classified as current financial assets as of June 30, 2024, the Company believes its cash and cash equivalents and deposits will be sufficient to fund its operations into 2026 and therefore for at least twelve months following the unaudited interim condensed consolidated financial statements' publication.

    Revenues and Other Income: Consolidated revenues and other income were $16.0 million for the six months ended June 30, 2024 compared to $5.6 million for the six months ended June 30, 2023. This $10.4 million increase between the six months ended June 30, 2023 and 2024 was mainly attributable to (i) recognition of a $12.3 million revenue in 2024 based (a) on the progress of our performance obligation rendered under the first research plan of the Joint Research and Collaboration Agreement (the "JRCA") signed with AstraZeneca Ireland Limited (AZ Ireland) and (b) the reaching of a development milestone under the License Agreement signed with Servier, while revenues recognized for the six months ended June 30, 2023 were immaterial, (ii) a decrease of research tax credit of $1.1 million due to a decrease of eligible expenses, and (iii) the recognition in the six-month periods ended June 30, 2023 of $0.8 million representing the portion of an initial payments from BPI corresponding to a grant pursuant to our grant and repayable advance agreement with BPI signed in March 2023.

    R&D Expenses: Consolidated R&D expenses were $45.8 million for the six months ended June 30, 2024, compared to $43.6 million for the six months ended June 30, 2023. R&D personnel expenses decreased by $0.8 million from $20.0 million in 2023 to $19.2 million in 2024 primarily due to a decrease in the average unit fair value of stock options and free share awards vesting between the two periods. R&D purchases, external expenses and other increased by $3.1 million (from $23.6 million in 2023 to $26.7 million in 2024) mainly related to increase in manufacturing activities to support our R&D pipeline.

    SG&A Expenses: Consolidated SG&A expenses were $9.0 million for the six months ended June 30, 2024 compared to $8.9 million for the six months ended June 30, 2023. SG&A personnel expenses decreased by $0.2 million (from $4.0 million in 2023 to $3.8 million in 2024), with a $0.4 million increase in salaries being offset by a $0.6 million decrease in stock-based compensation expenses. SG&A purchases, external expenses and other increased by $0.3 million (from $4.9 million in 2023 to $5.2 million in 2024).

    Other operating income and expenses: Other operating income and expenses were a $0.7 million net income for the six months ended June 30, 2024 compared to a $0.1 million net expense for the six months ended June 30, 2023. Other operating income and expenses decreased by $0.8 million primarily due to the recognition of costs related to a litigation of $0.5 million in 2023.

    Net financial gain (loss): We had a consolidated net financial gain of $18.0 million for the six months ended June 30, 2024, compared to a $10.2 million loss for the six months ended June 30, 2023. This $28.3 million difference reflects mainly (i) a $14.3 million gain in change in fair value of SIA derivative instrument, (ii) a $3.2 million increase in gain from our financial investments, (iii) a $4.3 million gain in change in fair value of EIB tranche A and B, , (iv) a $5.5 million decrease of the loss in fair value of our investment in Cibus and (vi) the loss in fair value measurement on Cytovia convertible note recognized in the six months period ended June 30, 2023 of $6.8 million, partially offset by (i) a $1.3 million interest expense on EIB Tranche A and Tranche B loans and (ii) a $0.7 million increase in foreign exchange loss, and (iii) a decrease in net foreign exchange gain of $3.5 million.

    Net income (loss) from discontinued operations: Net income from discontinued operations of $8.4 million for the six months ended June 30, 2023 corresponded to Calyxt's results. Since Calyxt has been deconsolidated since June 1, 2023, there is no longer any "Income (loss) from discontinued operations" for the six months ended June 30, 2024.

    Net Income (loss) Attributable to Shareholders of Cellectis: Consolidated net loss attributable to shareholders of Cellectis was $19.6 million (or a $0.24 loss per share) for the six months ended June 30, 2024, compared to a $41.8 million loss (or a $0.78 loss per share) for the six months ended June 30, 2023, of which $57.6 million was attributed to Cellectis continuing operations. The $29.5 million change in net loss was primarily driven by (i) an increase in revenues and other income of $10.4 million, (ii) a decrease of $1.5 million in non-cash stock based compensation expense due to a decrease in the average unit fair value of stock options and free share awards vesting between the two periods, (iii) a $28.3 million change from a net financial loss of $10.2 million to a net financial gain of $18.0 million and (iv) a decrease in net other operating expense of $0.8 million, and (v) a $8.4 million decrease in net income from discontinued operations attributable to shareholders of Cellectis, partially offset by (i) an increase of $3.3 million in purchases, external expenses and other, and a (ii) an increase of $0.4 million in wages.

    Adjusted Net Income (Loss) Attributable to Shareholders of Cellectis: Consolidated adjusted net loss attributable to shareholders of Cellectis was $17.9 million (or a $0.22 loss per share) for the six months ended June 30, 2024, compared to a net loss of $36.7 million (or a $0.68 loss per share) for the six months ended June 30, 2023.

    Please see "Note Regarding Use of Non-IFRS Financial Measures" for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to adjusted net income (loss) attributable to shareholders of Cellectis.

    We currently foresee focusing our cash spending at Cellectis for 2024 in the following areas:

    • Supporting the development of our pipeline of product candidates, including the manufacturing and clinical trial expenses of UCART22, UCART20x22, UCART123 and potential new product candidates, and
    • Operating our state-of-the-art manufacturing capabilities in Paris (France), and Raleigh (North Carolina, USA); and
    • Continuing strengthening our manufacturing and clinical departments.



    CELLECTIS S.A.

    STATEMENT OF CONSOLIDATED FINANCIAL POSITION (unaudited)

    ($ in thousands)
     
      As of
      December 31, 2023 June 30, 2024
    ASSETS     
    Non-current assets     
    Intangible assets 671  653 
    Property, plant, and equipment 54,681  50,370 
    Right-of-use assets 38,060  33,671 
    Non-current financial assets 7,853  16,650 
    Total non-current assets  101,265  101,344 
    Current assets     
    Trade receivables 569  9,741 
    Subsidies receivables 20,900  14,958 
    Other current assets 7,722  7,587 
    Current deferred tax assets   710 
    Cash and cash equivalent and Current financial assets 203,815  272,806 
    Total current assets  233,005  305,803 
    TOTAL ASSETS  334,270  407,147 
    LIABILITIES     
    Shareholders' equity     
    Share capital 4,365  5,897 
    Premiums related to the share capital 522,785  606,146 
    Currency translation adjustment (36,690) (38,077)
    Retained earnings (304,707) (405,729)
    Net income (loss) (101,059) (19,627)
    Total shareholders' equity - Group Share 84,695  148,610 
    Non-controlling interests 0  0 
    Total shareholders' equity 84,695  148,610 
    Non-current liabilities     
    Non-current financial liabilities 49,125  58,348 
    Non-current lease debts 42,948  38,362 
    Non-current provisions 2,200  2,194 
    Non-current deferred tax liabilities 158  0 
    Total non-current liabilities  94,431  98,904 
    Current liabilities     
    Current financial liabilities 5,289  5,119 
    Current lease debts 8,502  8,357 
    Trade payables 19,069  18,213 
    Deferred revenues and deferred income 110,325  117,754 
    Current provisions 1,740  884 
    Current deferred tax liabilities   122 
    Other current liabilities 10,219  9,184 
    Total current liabilities  155,144  159,633 
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY  334,270  407,147 
     



    UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS

    For the three-month period ended June 30, 2024

    ($ in thousands, except per share amounts)
     
      For the three-month period ended June 30,
      2023* 2024
        
    Revenues and other income    
    Revenues 178  8,061 
    Other income 1,823  1,442 
    Total revenues and other income 2,001  9,504 
    Operating expenses    
    Research and development expenses (22,200) (23,518)
    Selling, general and administrative expenses (3,950) (3,882)
    Other operating income (expenses) 528  686 
    Total operating expenses (25,622) (26,714)
         
    Operating income (loss) (23,621) (17,211)
         
    Financial gain (loss) (5,844) (8,251)
         
    Income tax  (258) 193 
    Income (loss) from continuing operations (29,724) (25,270)
    Income (loss) from discontinued operations 13,083  0 
    Net income (loss) (16,641) (25,270)
    Attributable to shareholders of Cellectis (11,707) (25,270)
    Attributable to non-controlling interests (4,934) 0 
    Basic and diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share) (0.20) (0.28)
    Diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share) (0.20) (0.28)
    Basic and diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) 0.32  0.00 
    Diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) 0.32  0.00 
         
    Number of shares used for computing    
    Basic 55,583,768  89,852,142 
    Diluted 55,583,768  89,852,142 
           

    *These amounts reflect Calyxt's adjustments as presented in Cellectis 2023 20F (Note 3)



    Cellectis S.A.

    UNAUDITED STATEMENTS OF CONSOLIDATED OPERATIONS

    For the six-month period ended June 30, 2024

    ($ in thousands, except per share amounts)
     
      For the six-month period ended June 30,
      2023* 2024
        
    Revenues and other income    
    Revenues 317  12,589 
    Other income 5,242  3,412 
    Total revenues and other income 5,560  16,002 
    Operating expenses    
    Research and development expenses (43,614) (45,841)
    Selling, general and administrative expenses (8,914) (8,986)
    Other operating income (expenses) (83) 721 
    Total operating expenses (52,612) (54,107)
         
    Operating income (loss) (47,053) (38,105)
         
    Financial gain (loss) (10,246) 18,023 
         
    Income tax  (258) 455 
    Income (loss) from continuing operations (57,557) (19,627)
    Income (loss) from discontinued operations 8,392  0 
    Net income (loss) (49,165) (19,627)
    Attributable to shareholders of Cellectis (41,781) (19,627)
    Attributable to non-controlling interests (7,384) 0 
    Basic net income (loss) attributable to shareholders of Cellectis, per share ($/share) (0.78) (0.24)
    Diluted net income (loss) attributable to shareholders of Cellectis, per share ($/share) (0.78) (0.24)
    Basic net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) 0.29  0.00 
         
    Diluted net income (loss) attributable to shareholders of Cellectis from discontinued operations, per share ($ /share) 0.29  0.00 
         
    Number of shares used for computing    
    Basic 53,541,010  80,881,026 
    Diluted 53,541,010  80,881,026 
           

     *These amounts reflect Calyxt's adjustments as presented in Cellectis 2023 20F (Note 3)

    Note Regarding Use of Non-IFRS Financial Measures

    Cellectis S.A. presents adjusted net income (loss) attributable to shareholders of Cellectis in this press release. Adjusted net income (loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to net income (loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS.

    Because adjusted net income (loss) attributable to shareholders of Cellectis excludes non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis' financial performance. Moreover, our management views the Company's operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of non-cash stock-based expenses from Net income (loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of non-cash stock- based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Cellectis.



    RECONCILIATION OF IFRS TO NON-IFRS NET INCOME (unaudited)

    For the three-month period ended June 30, 2024

    ($ in thousands, except per share data)
     
      For the three-month period ended June 30,
       2023* 2024
        
    Net income (loss) attributable to shareholders of Cellectis  (11,707) (25,270)
    Adjustment:

          
    Non-cash stock-based compensation expense attributable to shareholders of Cellectis 3,140  830 
    Adjusted net income (loss) attributable to shareholders of Cellectis (8,567) (24,440)
    Basic adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (0.15) (0.27)
    Basic adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($ /share)  (0.04) 0.00 
         
    Weighted average number of outstanding shares, basic (units) (1) 55,583,768  89,852,142 
         
    Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1) (0.15) (0.27)
    Diluted adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($/share)  (0.04) 0.00 
         
    Weighted average number of outstanding shares, diluted (units) (1) 55,583,768  89,852,142 
     

     

    *These amounts reflect Calyxt's adjustments as presented in Cellectis 2023 20F (Note 3)

    RECONCILIATION OF IFRS TO NON-IFRS NET INCOME (unaudited)

    For the six-month period ended June 30, 2024

    ($ in thousands, except per share data)

      For the six-month period ended June 30,
      2023* 2024
        
    Net income (loss) attributable to shareholders of Cellectis  (41,781) (19,627)
    Adjustment:      
    Non-cash stock-based compensation expense attributable to shareholders of Cellectis 5,119  1,717 
    Adjusted net income (loss) attributable to shareholders of Cellectis (36,662) (17,910)
    Basic adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (0.68) (0.22)
    Basic adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($ /share)  (0.09) 0.00 
         
    Weighted average number of outstanding shares, basic (units) (1) 53,541,010  80,881,026 
         
    Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1) (0.68) (0.22)
    Diluted adjusted net income (loss) attributable to shareholders of Cellectis from discontinued operations ($/share)  (0.09) 0.00 
         
    Weighted average number of outstanding shares, diluted (units) (1) 53,541,010  80,881,026 
     

     *These amounts reflect Calyxt's adjustments as presented in Cellectis 2023 20F (Note 3)

    About Cellectis  

    Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis' headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).  

    Forward-looking Statements     

    This press release contains "forward-looking" statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "future," "projection," "will," " may," "would," "expect," and "believe" or the negative of these and similar expressions. These forward-looking statements are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the advancement, timing and progress of clinical trials, the timing of our presentation of clinical data, the potential of our candidate products programs and CLLS52, the outcome of the arbitration proceedings against Servier, and the sufficiency of cash to fund operations. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development, including the risk of losing the orphan drug designation if it is established that the product no longer meets the orphan drug criteria before market authorization is granted (if any). With respect to our cash runway, our operating plans, including product candidates development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.      

    For further information on Cellectis, please contact:

    Media contacts:  

    Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, [email protected]   

    Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93    

    Investor Relations contact: 

    Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, [email protected]

    Attachment

    • 20240805_Cellectis Reports Financial Results for Second Quarter 2024 - V0508[7]


    Primary Logo

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN
    $CLLS

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    11/20/2024Sell → Neutral
    UBS
    AstraZeneca PLC
    $AZN
    11/6/2024Sell → Hold
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    9/13/2024Hold → Sell
    Deutsche Bank
    AstraZeneca PLC
    $AZN
    5/30/2024$97.00Buy
    Goldman
    AstraZeneca PLC
    $AZN
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    $CLLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

      UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, 20241; cash runway projection into 2027Conference call scheduled for 8:00 am ET / 2:00 pm CET on November 5, 2024 NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company

      11/4/24 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

      NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately. "We're thrilled to welcome Dr. Kilcoyne to Cellectis. He is a strategic, forward-thinking drug developer who is passionate about delivering life-saving therapies to patients. His clinical vision and proven leadership, as well as his extensive experience, will strengthen our clinical development efforts as we advance our product pipeline of next-generation

      8/7/24 2:00:00 AM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $CLLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $CLLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

      Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs. BCG alone Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​ The trial was not statistically powered to formally test ov

      5/9/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

      AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positi

      5/7/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results will be shared with regulatory authorities Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients w

      5/7/25 2:30:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $CLLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Cellectis S.A. (Amendment)

      SC 13D/A - Cellectis S.A. (0001627281) (Subject)

      5/21/24 4:19:05 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

      SC 13G/A - Cellectis S.A. (0001627281) (Subject)

      2/14/24 5:07:22 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cellectis S.A. (Amendment)

      SC 13G/A - Cellectis S.A. (0001627281) (Subject)

      2/14/24 2:24:22 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    $CLLS
    Financials

    Live finance-specific insights

    See more
    • Cellectis to Report First Quarter Financial Results on May 12, 2025

      NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis' website: https://www.cellectis.com/en/investors/press-releases/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at [email protected]      About Cellectis  Ce

      5/6/25 4:30:00 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $AZN
    $CLLS
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/9/25 11:23:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Cellectis S.A.

      6-K - Cellectis S.A. (0001627281) (Filer)

      5/6/25 4:35:08 PM ET
      $CLLS
      Biotechnology: Pharmaceutical Preparations
      Health Care